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The human immunodeﬁciency virus (HIV), the causative agent of acquired immunodeﬁciency
syndrome (AIDS), relies heavily on protein–protein interactions in almost every step of its
lifecycle. Targeting these interactions, especially those between virus and host proteins,
is increasingly viewed as an ideal avenue for the design and development of new therapeutics.
In this tutorial review, we outline the lifecycle of HIV and describe some of the protein–protein
interactions that control and regulate each step of this process, also detailing eﬀorts to develop
therapies that target these interactions.
Introduction
There are multiple compounds currently on the market that
target HIV, with the majority down-regulating the activity of a
viral enzyme associated with the ailment. As a result, these
therapies are very susceptible to emergence of drug resistance
strains, of particular concern with HIV, whose genome-
replication process has a high error rate that encourages
mutations. This is reﬂected in drug-resistance rates of up
to 19% to some HIV inhibitors,1 and a transmitted drug
resistance of over 9%.2 The World Health Organisation
estimates 33 million people to be infected by HIV worldwide,
resulting in 2 million deaths a year; given the number of
Fig. 1 The HIV lifecycle. HIV entry involves binding and inter-
nalisation of the viral capsid into the host, where the HIV genome is
reverse transcribed from RNA to DNA and integrated into the host’
genome. The proteins necessary for the production of viral progeny are
produced by the host (through transcription and translation of the
integrated viral genome), assembled and released. The immature particles
undergo maturation and go on to infect other cells in the host.
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infected individuals harbouring drug-resistant strains, there is
now a pressing need for the development of novel therapies
that enable new approaches to targeting HIV.
As with other viruses, HIV heavily relies on usurping the
host’s cellular machinery at almost every stage of its lifecycle
(Fig. 1). These processes typically occur through the inter-
action of viral and host proteins, or homodimeric/multimeric
viral protein interactions. The reliance on protein–protein
interactions allows the possibility of developing novel
therapeutic agents that inhibit HIV by targeting these
interactions. There are however, major obstacles to this
approach; the interacting surfaces involved are typically large
and featureless, making logical design of inhibitors extremely
challenging.3 Even with crystal structures of the interacting
protein pair at hand, uncovering the region to target with a
small molecule is not trivial. The alternative to logical design is
high-throughput screening, which enables all potential binding
sites on the target proteins to be assessed and assayed, with the
most potent being identiﬁed by the system (rather than
predetermined).4 This approach is increasingly used in drug
discovery, with many modern drug candidates initially
uncovered by screening of molecular libraries, with the lead
compounds being optimised through conventional medicinal
chemistry. Both approaches have been successfully applied to
development of HIV therapies currently in the market.
Here we detail the steps in the HIV lifecycle that have been
(or are currently being) targeted for the development of novel
therapeutics that function by inhibiting speciﬁc protein–
protein interactions. As the majority of current HIV therapies
target enzymatic activity, there is much potential for inhibitors
with this alternative mode of action.
The virus
HIV is part of the Lentivirus genus and a member of the
retrovirus family. The genetic information of the virus is
therefore stored on two copies of positive-sense RNA strands.
The HIV genome (Fig. 2) contains nine reading frames, three
of which (Gag, Pol and Env) encode polyproteins that are
further proteolyzed to give a total of 15 proteins that are
required for the lifecycle of HIV. The four Gag (matrix,
capsid, nucleocapsid, p6) and two Env (gp120, gp41) proteins
form structural components that make up the virus core and
outer membrane. Pol encodes three enzymes (reverse
transcriptase, protease, integrase) that provide essential
functions in the virus lifecycle (not available via the host
machinery), which are also encapsulated within the virus
particle. The six other HIV proteins (Vif, Vpr, Nef, Tat,
Rev, Vpu) are accessory proteins that play key roles at various
points during the virus lifecycle. The virus can therefore be
considered as a molecular entity that consists of 15 proteins
and RNA.5
The virus itself (Fig. 3) is roughly spherical, with a diameter
of 120 nm. The two RNA strands at the core of the virus
particle are tightly bound to nucleocapsid proteins (NC, also
known as p7) and are surrounded by a conical capsid,
composed of the p24 capsid protein (CA). Within the capsid,
the enzymes and proteins needed by the virus (and not
available in the host) are present; these include reverse
transcriptase, integrase, protease, Vif, Vpr, Nef and p6. The
capsid is surrounded by the matrix protein (MA), which
ensures the integrity of the virus particle. The viral envelope
surrounding the matrix is made up of phospholipids taken
from the host’s membrane during budding, and is embedded
with gp41 proteins. The viral envelope is completed by gp120,
which non-covalently associates to gp41. The envelope
proteins arrange into homotrimeric ‘‘spikes’’ that are essential
for entry into the host cell.
Viral entry
Infection begins with virus entry into the host. This is an
intricate, complex, multistep process that involves the viral
envelope proteins gp120 and gp41, and corresponding
receptors on the host cell. The envelope proteins are synthesized
as a single polypeptide (gp160) that is cleaved during its transit
to the cellular membrane. The gp41 protein is anchored to,
and spans the viral membrane, with its extracellular domain
binding (non-covalently) to gp120. These viral proteins
Fig. 2 The HIV genome. A single RNA strand codes for the 15 proteins of the HIV lifecycle, utilising all three reading frames. There is
considerable overlap in the genetic information, which allows the controlled production of speciﬁc proteins (through modulation of mRNA
splicing), as they are need during the lifecycle. The Pol proteins are produced from a Gag-Pol mRNA by a frame-shift during translation.
Fig. 3 The HIV virus. The virus is roughly spherical with the RNA
genome enclosed within a conical capsid that also contains the
enzymes and proteins needed for infection. These include reverse
transcriptase, integrase, protease, as well as p6, Vif, Vpr and Nef.
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associate into homotrimers6 that mediate binding and entry to
target cells. The primary receptor for HIV is the glycoprotein
CD4, which is expressed on the surface of T helper cells,
regulatory T cells, monocytes, macrophages and dendritic
cells. CD4 normally functions as a co-receptor (with the T
cell receptor) to activate T-cells following interaction with
antigen-presenting cells. The binding of gp120 (through a
highly conserved, unglycosylated region)7 to CD4 initiates
viral entry, and causes gp120 to undergo a dramatic change
in conformation (whilst still maintaining its association with
gp41)8 to expose a second (co-receptor) binding site. The
primary co-receptors of HIV are CCR5 and CXCR4,9 both
chemokine receptors and members of the G protein-coupled
receptor family. Diﬀerent strains of HIV can display selectivity
for a particular co-receptor; those using CCR5 are termed
R5-tropic (or M-tropic as CCR5 is found mostly in
macrophages), those using CXCR4 are termed X4-tropic
(or T-tropic, as CXCR4 receptors are typically found in T
lymphocytes). Those that bind either CCR5 or CXCR4 are
termed mixed-tropic (or X4R5). Following binding to the
co-receptor, gp120 (now anchored to the host by two
protein–protein interactions) undergoes a further confor-
mational shift that brings a hydrophobic region in gp41 close
to the host cell, resulting in its insertion into the host cell’s
membrane. This insertion causes an energetically favoured
conformation rearrangement of the heptad repeat regions
(HR1 and HR2) of gp41,10 which brings the transmembrane
region of gp41 (in the virus membrane) in contact with the
gp41 hydrophobic fusion peptide (inserted into the host’s
membrane). Thus the fusion pore is formed, enabling the virus
capsid to enter the cell.
There are several protein–protein interactions that are
central to HIV entry: the binding of gp120 to CD4, the binding
of gp120 to the co-receptor and the internal interactions of
gp41 during membrane fusion. Targeting these interactions
holds considerable potential for the treatment of HIV,
especially for individuals harbouring strains of HIV that are
resistant to drugs targeting reverse transcriptase or protease
(the majority of therapeutics currently used). There are
currently two entry-inhibiting drugs (Maraviroc and Fuzeon)
on the market, with several undergoing clinical trials.11 The
HIV envelope proteins contain regions that are highly diverse
and variable in their primary sequence, as well as highly
conserved regions (where any mutations result in non-
functional viruses). This variability is a considerable challenge
facing entry inhibitors, which results in widely diﬀering patient
baseline sensitivity and response to inhibitors targeting
envelope proteins.12
The ﬁrst point of contact between HIV and the host is the
interaction of CD4 with gp120, which has been extensively
targeted using a variety of strategies, without yielding any
compounds in the clinic.11 The next point of intervention in
HIV entry is the interaction of gp120 with its chemokine
co-receptor (CCR5 or CXCR4). The importance of CCR5
for (R5-tropic) HIV entry is demonstrated by a well-established
association between a 32 base pair deletion variant of CCR5
(CCR5-D32) in 5–14% of individuals of European
Caucasians, and protection from HIV infection.13 The
presence of one copy of this allele has been shown to delay
the onset of AIDS by around 2 years, while those with two
copies of the CCR5-D32 allele have strong protection against
R5-tropic HIV strains and may not become infected at all. As
these individuals (with the CCR5-D32 allele) are healthy, it is
suggested that CCR5 is largely dispensable. As HIV has not
existed long enough in the population to exert selective
pressure for the CCR5-D32 allele, this mutation is thought
to have arisen as a result of either bubonic plague or smallpox,
which may explain the intense selectivity observed in
Europeans.14 Unlike CCR5 however, CXCR4 is essential for
the viability of multiple physiological processes, and deletion
of the gene causes embryonic death in mice.15
The only inhibitor of the interaction of gp120 with a
chemokine co-receptor is Maraviroc (Fig. 4, UK-427,857,
Pﬁzer, Inc.),16 a potent (IC90 of 2 nM), orally bioavailable
antagonist of CCR5 that inhibits viral entry by R5- and
mixed-tropic strains of HIV. The compound is the product
of medicinal chemistry development and optimisation of a
lead identiﬁed by high-throughput screening. It is typically
prescribed to patients with R5 tropic HIV strains that are
resistant to multiple antiretroviral agents. As Maraviroc binds
a human chemokine receptor (rather than a viral protein), it is
expected to be less susceptible to acquired resistance.
However, Maraviroc-resistant strains of HIV (with mutations
at residues 316 and 323 in V3 loop of gp120) have been
identiﬁed in primary isolates17 that are seemingly able to
use Maraviroc-bound CCR5 for entry. Another source of
resistance observed in patients with virological failure is
changes in viral tropism from R5 to X4 or mixed-tropic.17
An additional complication is that as the disease progresses,
there is a natural shift form R5 to X4-tropic viruses;18 as
Maraviroc is approved for use in patients with multiple-drug
resistant stains of HIV (typically in the latter stages of the
disease), the possibility of treatment failure as a result of
X4-tropic viral outgrowth is increased. There have therefore
been suggestions that Maraviroc may be better utilized in
patients at earlier stages of HIV. There are several other entry
inhibitors currently being developed that target the interaction
of gp120 with CCR5.11 Antibodies that block the CCR5
receptor and prevent binding of gp120 are another promising
class of entry inhibitors that are currently undergoing clinical
trials.19
Fig. 4 Maraviroc. A viral entry inhibitor that prevents the interaction
of the viral gp120 protein with its chemokine co-receptor CCR5.
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Although there are no current clinical trials of compounds
that inhibit the interaction of gp120 with CXCR4,11 there
are several in development.20 These compounds, when
administered in combination with a CCR5 inhibitor, may
provide an eﬀective method for inhibiting HIV entry. Such a
combination therapy would be eﬀective regardless of viral
tropism and would eliminate the selective pressure for
X4-tropic HIV strains in patients taking inhibitors targeting
R5 strains.
The other HIV entry inhibitor currently on the market is
Fuzeon (Enfuvirtide, Roche), a linear 36 amino acid peptide,
derived from the HR2 region of gp41.21 Fuzeon is a membrane
fusion inhibitor that was approved for use in 2003. Due to its
cost and the need for intravenous administration, it is typically
used as salvage therapy in patients with multi-drug resistant
HIV. As outlined above, gp41 mediated membrane fusion
involves the formation of a six-helix bundle made up of the
HR1 and HR2 domains of the three gp41 proteins of the
functional trimeric spikes. Fuzeon works by competitively
binding to HR1, thus preventing the formation of the six-helix
bundle that is necessary for membrane fusion. Acquired
resistance requires mutations in the 10 amino acid motif
between residues 36 and 45 of gp41. As this 10 amino acid
motif is also critical for viral fusion, fuzeon-resistant mutants
show poor replicative capacity compared with wild type.
Clinical isolates have therefore shown variations in sensitivity
to Fuzeon, but primary resistance has not been observed.22
There are several other fusion inhibitors currently in
development.11 These include several ‘‘next generation’’
peptides that have improved eﬃcacy and are active against
some fuzeon-resistant strains.23 As these compounds target a
diﬀerent part of gp41 (to that targeted by fuzeon) there is
potential for the development of synergistic therapies based on
entry inhibitors.
Inhibition of the host’s antiviral defences
There exists in each host cell sophisticated defence mechanisms
that oﬀer protection from viral infections. Viruses in turn have
evolved infectivity factors that inactivate the host’s innate
defences, allowing infection to proceed unchecked. The HIV
viral infectivity factor (ViF)24 is present in the capsid, and
neutralises a potent antiviral pathway present in nonpremissive
host cells (T lymphocytes, macrophages and several leukemic
T-cell lines). In the absence of ViF, this antiviral pathway is
suﬃcient to eﬀectively inactivate HIV-1,25 and thus needs to
be deactivated (by the virus). The key factor in this antiviral
response is APOBEC3G,26 a host protein that functions by
deaminating cytidines from the negative strand of HIV-1
DNA during reverse transcription. Deamination of cytidine
converts it to a uridine, thus rapidly introducing a very large
number of mutations into the viral genome (GC base-pairs are
eﬀectively changed to AT base pairs) rendering the viral
genomic information useless, and coding for nonsense. ViF
binds to APOBEC3G, inducing the rapid degradation of
APOBEC3G via a proteasome-dependant pathway, thus
silencing the host’s antiviral defences.27 Inhibiting this
protein–protein interaction is expected to restore the host’s
defences and inhibit HIV infection. This promise has been
demonstrated by a compound recently uncovered through
screening a library of 30 000 small molecules for inhibitors
of the ViF/APOBEC3G interaction.28 The compound was
shown to antagonise ViF function and reduce viral infectivity
by increasing APOBEC3G incorporation into virions,
enhancing cytidine deamination of the viral genome and
inhibiting HIV-1 replication. Although the presence of
permissive cells (those that do not contain APOBEC3G and
its antiviral activity) limits the beneﬁt of this approach as a
single therapy, such agents will be of potential beneﬁt in
combination therapies.
Reverse transcription
HIV stores its genomic information as RNA, whereas the host
uses DNA. In order to transplant viral genomic information
into the host cells, it must ﬁrst be copied from single-strand
RNA onto duplex DNA, in a process called reverse transcription.
As the host lacks the cellular machinery to carry out this
conversion (genomic information typically ﬂows from DNA to
RNA to protein; the central dogma of molecular biology), the
virus needs to supply its own reverse transcriptase enzyme for
this purpose. HIV reverse transcriptase (Fig. 5) is a hetero-
dimer, made up of a 560-residue subunit (p66) and a
440-residue subunit (p51); the dimeric form is essential for
all enzymatic activity.29 The functional complex is generated
from a p66 homodimer by HIV protease, which cleaves one of
the C-terminal RNase H domains during maturation of the
virus particle. The resulting p66/p51 heterodimer is a multi-
functional enzyme, with polymerase and nuclease activity. It is
interesting to note that the p66 subunit performs both the
polymerase and nuclease functions, while the p51 subunit is
inactive, but acts as structural support.30
All reverse transcription reactions require a primer with a
free 30-hydroxyl group to initiate cDNA synthesis; HIV
reverse transcriptase uses a lysine tRNA as the replication
Fig. 5 HIV reverse transcriptase bound to DNA. The enzyme is a
p66/p51 heterodimer. The RNase H domain (orange) of p66 (yellow) is
highlighted; p51 is coloured red. This ﬁgure was made using PyMol
1.2 and structure 2HMI from The Protein Data Bank.
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primer (Fig. 6A).31 The 18 nucleotides of the tRNALys,3 anneal
to the complementary primer binding (PB) region in the viral
genome (in the untranslated leader region), initiating reverse
transcription (Fig. 6B). As the single strand DNA is synthesized,
the complimentary single stand RNA (viral genome) is
degraded by the RNase H function of the enzyme. The
DNA polymerase activity of HIV reverse transcriptase
completes the synthesis of the double strand DNA copy of
the viral genome32 (Fig. 6C–G), adding long terminal repeats,
used by HIV integrase to incorporate the viral genome into
that of the host.
The HIV reverse transcriptase is essential to the virus, and
therefore an attractive target for antiviral therapies. A large
group of current HIV therapies on the market target reverse
transcriptase, with the majority being nucleoside or nucleotide
analogues, such as azidothymidine (AZT)33 or Didanosine
(ddI).34 These compounds35 all lack the 30 hydroxyl group of
deoxyribose, thus their incorporation into the growing oligo-
nucleotide causes chain termination (there is no 30 hydroxyl
group on the inhibitor to bind the 50phosphate group of the
next incoming nucleotide). Although an integral component of
almost all current HIV treatment programs, these inhibitors
are very susceptible to the evolution of drug-resistant strains
of HIV. The rapid emergence of mutations conferring
drug-resistance to HIV observed in the clinic is due to the
poor ﬁdelity of the reverse transcription process, estimated to
be around 1 mistake per 1700 bases, and as high as 1 in
70 when copying certain regions of the genome.36 The high
error rate is the result of the absence of an intrinsic
exonucleolytic proofreading mechanism in HIV reverse
transcriptase. This is actually advantageous to the virus, as it
allows the rapid production of mutant strains that undergo
growth advantage selection in the host. Each time the reverse
transcriptase copies the HIV genome it has the potential to
make mistakes that introduce mutations into the proteins of
the progeny that may confer a growth advantage on the
resulting virus (through resistance to a drug or better evasion
of the host immune system). The resulting strain will have a
growth advantage in the host and become dominant. The low
ﬁdelity of HIV reverse transcriptase is (ironically) essential for
Fig. 6 Mechanism of HIV reverse transcription. (A) A lysine tRNA binds to the primer binding (PB) region on the RNA genome. (B) As DNA is
synthesized (reverse transcription only occurs in the 30->50 direction), the complimentary RNA strand is degraded. (C) The DNA–tRNA hybrid is
transferred to the 30 end of the template, binding to a complementary site. (D) The viral single strand RNA template is degraded except for the
polypurine (PP) section. (E) PP serves as a primer for second strand synthesis. (F) The tRNA is degraded. Note the matching PB sites on the ﬁrst
and second strand. (G) The ﬁrst and second DNA strands hybridise at their PB site allowing double strand DNA synthesis to be completed (each
serving as template for the other) by the DNA polymerase function of reverse transcriptase. (G) Reverse transcriptase will add LTR regions at each
terminus of the DNA.
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the inhibitory activity of nucleoside and nucleotide analogues,
as it enables their incorporation into the reverse transcribed
DNA chain without subsequent excision and repair.
A promising alternative strategy for inhibition of HIV
reverse transcriptase is to disrupt the protein–protein inter-
action between the p66 and p51 subunits, as the heterodimeric
form is required for enzyme function. There have been two
examples of this approach in the literature,37 one a small
molecule derived via structure-based ligand design,37c and
the other a linear peptide derived from a structural motif
located between residues 284 and 300 of p51.37b,c Both of these
compounds are far from the clinic, but they represent a start
for the development of compounds that target the dimerisation
of p66 and p51. Another interesting reverse transcriptase
inhibitor is the thymine derivative TSAO,38 which acts by
destabilising the heterodimeric form of reverse transcriptase,
leading to the loss of DNA binding activity. It is worth
mentioning that regardless of structure or mechanism of
action, all compounds targeting reverse transcriptase will be
susceptible to acquired drug resistance, due to the high
mutation rates of HIV genome replication.
Integration
Integration ﬁnalises infection, with the viral (reverse transcribed)
cDNA being incorporated into the host’s genome. This occurs
via a series of carefully coordinated reactions, mediated by the
HIV integrase enzyme. As with reverse transcription, there are
no functional equivalents to integrase in the host, the enzyme
is therefore essential to the HIV lifecycle. Integrase is made up
of three domains: the zinc-binding N-terminal domain, the
catalytic core domain and the DNA-binding C-terminal
domain.39 The catalytic core domain contains a conserved
D64, D116, E152 ‘‘catalytic triad’’ that bind up to two divalent
metal ions (Mg2+ or Mn2+). These metal ions are essential for
integrase activity and are present in other DNA processing
enzymes in nature. Structural studies suggest that the active
integrase complex is a multimer (possibly a homodimer or
tetramer).39
The reverse transcribed viral DNA is linear, blunt-ended
and contained within a pre-integration complex including
integrase, matrix and Viral Protein R (Vpr). The ﬁrst step of
integration is 30-end processing, in which integrase recognises
speciﬁc sequences in the long terminal repeats (LTRs) of the
viral cDNA, and cleaves two nucleotides from the 30 end of
each strand to expose terminal hydroxyl groups on the
overhanging termini. The viral DNA remains bound to the
multimeric integrase complex, and is transported into the
nucleus via the multiple nuclear localisation signals in
integrase, matrix and Vpr.40 This initiates DNA strand
transfer, which involves the insertion of processed viral cDNA
ends into the host chromosomal DNA. Integrase catalyses the
attack by the 30-hydroxyl groups (at the termini of the viral
cDNA strands) on a pair of phosphodiester bonds in the host’s
chromosomal DNA, with the site of attack on each strand
being separated by 5 base pairs.41 Strand transfer42 produces
an integration intermediate in which the 30-end of each viral
cDNA strand is joined to the host’s chromosome, with two
overhanging bases on the 50-ends and a gap to the host
chromosomal DNA. Integration is completed by the host’s
DNA repair enzymes trimming the overhanging bases, ﬁlling
in the single strand gaps to the host chromosome, and ligating
the ends together. There is no speciﬁc site of attack on the
host’s chromosome and integration can occur into any
location. The integrated viral genome will lay dormant,
especially in the latent stages of the disease, until cellular
transcription factors enhance transcription of the viral genome
and trigger the production of viral proteins (discussed in detail
in the next section).
The only integrase inhibitor currently on the market is
Raltegravir (Isentress, Merck & Co),43 an orally bioavailable
hydroxypyrimidinone carboxamide (Fig. 7). Raltegravir acts
by binding to the divalent metal ions in the integrase catalytic
core domain, preventing their interaction with DNA and
inhibiting the strand transfer step. Inhibition of integrase by
Raltegravir is followed by a very strong reduction in viral
loads; however, resistance has evolved readily in the clinic,44
necessitating the development of second-generation inhibitors
or alternative strategies for targeting integrase.45 There have
been attempts to inhibit integrase activity by disrupting the
dimerization of the enzyme with peptides derived from the
interface region of the catalytic domain of the enzyme.46 These
peptides were inhibitors of the 30-endonuclease activity of the
enzyme (IC50 values in the low mM range), and were found to
inhibit the cross-linking of the dimeric form of integrase.
Another peptide inhibitor of integrase dimerisation is
Indolicidin, a naturally occurring, 13-mer antimicrobial
peptide that inhibits both the 30-endonuclease activity and
strand transfer steps of integrase. Further derivatisation and
optimisation of this peptide have substantially improved its
activity (IC50) from 60 mM to 600 nM.
47 But the relative ease
with which Raltegravir-resistance has evolved in the clinic44
strongly suggests that direct targeting of the HIV integrase
enzyme may not be the best approach for inhibition of the
integration step. As integration is a highly organised, multistep
process requiring several host factors,48 a better approach may
be to indirectly target integrase by inhibiting its interaction
with an essential host protein. One such co-factor is
LEDGF/p75 (lens epithelium-derived growth factor), whose
interaction with integrase modulates the tethering of the
pre-integration complex to chromatin; LEDFG/p75 binds to
chromatin via a PWWP domain in its N-terminus, and binds
to integrase through a domain in its C-terminus. This inter-
action has been shown to be crucial for HIV integrase activity
via RNAi and knockout studies. An attractive alternative
approach to inhibition of integrase would be to uncover small
molecules that are capable of inhibiting this protein–protein
Fig. 7 Raltegravir. The only integrase inhibitor currently on the
market, Raltegravir inhibits the integration of integrase with its
DNA substrate.
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interaction. Such a compound was recently identiﬁed by
analysis of the co-crystal structure of HIV integrase catalytic
core domain with the C-terminus of LEDGF/p75; this
was followed by virtual screening of a library of 200 000
compounds, and the lead compounds were further optimised
by rational design.49 The most potent inhibitor blocked the
replication of primary isolates of HIV with an IC50 of 580 nM,
by binding to integrase and inhibiting its essential interaction
with LEDGF/p75. Although the lead compound was found to
be active against HIV strains resistant to Raltegravir, a double
point mutation in integrase (A128T, E170G) is suﬃcient for
the virus to become fully resistant to the inhibitor. This
demonstrates the pitfalls of targeting binding pockets on viral
proteins, which have an exceptionally high mutation rate, and
therefore enable the virus to escape the eﬀects of a single
compound. A better approach may have been to develop
compounds that bind to LEDGF/p75 and inhibit/block its
interaction with integrase, as the host protein will have a far
lower mutation rate, thus its binding pockets will be more
robust and durable (than those on viral proteins).
Transcription and translation
Transcription of HIV genes from the integrated viral DNA
(known as the provirus) requires several host and viral
proteins. The 50 LTR of the viral genome contains the HIV
promoter, as well as sites for several host transcription factors.
Among these, the binding site(s) for NF-kB (a host protein
complex that controls DNA transcription) play a central role
in mediating and inducing HIV gene expression. Interestingly,
HIV strains have co-evolved with variations in their
LTR promoter-proximal region. The HIV-1 subtype E that
predominates in Asia contains one NF-kB binding site, the
LTR from subtype C that predominates in Africa contains
three NF-kB binding sites, and the North American subtype B
contains two NF-kB binding sites. NF-kB and other cellular
factors determine the rate of transcription from the integrated
viral genome, and variations in their intracellular levels (in
various cell types, or points in their lifecycle) is thought to be a
key factor in determining whether the provirus is laying
dormant or actively replicating. Despite the eﬀective use of
host signalling pathways to facilitate and enhance transcription
of the integrated viral genome, the production of elongated
transcripts is quite ineﬃcient. The viral protein Tat
(Trans-Activator of Transcription) plays a key role in enhancing
and rapidly up-regulating transcription. Initially, only a small
number of transcripts are produced, resulting in the build up
of Tat, which binds cellular kinases that trigger the phos-
phorylation of the C-terminal domain of the largest subunit of
RNA polymerase II. This results in a dramatic increase
(around 100-fold) in transcription of theB9 kb viral genome.
The complexity of the HIV genome (Fig. 2) results in the
possibility of more than 30 diﬀerent viral mRNA species in the
host cell during transcription and translation. As previously
mentioned, the expression of each of the multiple overlapping
genes within a single region of HIV proviral DNA is regulated
by mRNA splicing. These diverse, subgenomic species are
generated via four diﬀerent 50-splice sites and eight diﬀerent
30-splice sites. This leads to various fully spliced (B2 kb)
mRNAs that encode Rev, Tat or Nef; several partially spliced
(B4 kb) mRNAs that encode Env, Vif, Vpr, or Vpu; as well as
the full-length transcript (B9 kb) that encodes the Gag and
Gag-Pol genes. The viral mRNA is initially fully spliced by the
host’s splicing factors that retain and splice (in the nucleus) all
intron containing pre-RNA. To produce the partially spliced,
and full length viral mRNA (that encode the rest of the viral
proteins), the virus suppresses the host’s nuclear retention
mechanism to enable the translocation of intron-containing
unspliced and partially spliced mRNA to the cytoplasm. This
is the role of the Rev (Regulator of Virion) protein50 that
functions by binding to the Rev Response Element (REE) in
the env-coding region of the HIV mRNA and enhancing the
export of unspliced mRNAs from the nucleus to the
cytoplasm. In the early phase of provirus transcription, all
the HIV mRNA is in fully spliced resulting in an increase in
the cellular levels of Rev, Tat and Nef. As already mentioned,
the up-regulation of Tat increases levels of full length mRNA,
while the increase in Rev activates the transport of unspliced
or partially-spliced mRNA to the cytoplasm, resulting in the
production of the rest of the HIV proteins.
Tat and Rev play essential roles in the transcription and
translation of the provirus genome (and therefore the lifecycle
of HIV), and there are examples of compounds that directly or
indirectly inhibit Tat and Rev in the literature.51 Such
inhibitors are unlikely to eﬀectively combat HIV infection
on their own, and will be redundant during the latent phase of
infection. They may however prove beneﬁcial in combination
with other therapeutic agents, especially to those in the latter
stages of infection.
Assembly and budding
The assembly and release (known as budding) of HIV from the
host occurs in a series of organised steps that are driven by the
viral Gag protein.52 Gag is necessary and suﬃcient for virus
assembly; in the absence of other components of HIV, Gag
drives the spontaneous assembly and release of spherical
virus-like particles. The Gag polyprotein is made up of four
domains: matrix (MA), capsid (CA), nucleocapsid (NC) and
p6, as well as two smaller spacer peptides SP1 and SP2. The
N-terminal MA domain of Gag binds to the host’s plasma
membrane where Gag–Gag interactions (and their intrinsic
sphere-forming properties) form the structural shell of
budding virus particles.53 The MA domain also recruits Env
glycoproteins to the host’s plasma membrane, ensuring the
presence of the HIV envelope proteins in the progeny virus
particles. The NC region of Gag recognises and binds the
dimeric full-length viral RNA transcript via a four stem-loop
element located at the end of the gag gene. Gag also binds to,
and actively directs the packaging of, other viral proteins (such
as Gag-Pol) into the assembling particle. Although Gag
enables the formation and assembly of viral spheres on
membrane surfaces, components of the host’s endosomal
sorting complex are essential for budding, which involves
separation of the nascent virion envelope from the cell
membrane, releasing the virus particle. TSG101 is a central
component of the endocytic machinery (ESCRT-I complex),
whose activity is normally mediated by the endosomal protein
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HRS (hepatocyte growth factor-regulated tyrosine kinase
substrate) binding via a PSAP motif. HIV mimics the binding
of HRS through a competing PTAP motif contained within
the p6 region of Gag, which enables the recruitment of
TSG101 and associated ESCRT-I complex proteins from their
normal site of action on the late endosome to the plasma
membrane to mediate budding.54 Studies have shown that
siRNA mediated ablation of TSG101 severely impairs viral
production by arresting the release of viral particles from the
plasma membrane of host cells, and disruption of the TSG101/
Gag interaction by mutation of the Gag PTAP motif also
blocks viral budding. There are currently no drugs on the
market that target this step of the HIV lifecycle. Our own
eﬀorts have focused on targeting the interaction between the
p6 region of Gag and TSG101. We have screened a library of
over 108 cyclic peptides,55 and have identiﬁed an inhibitor
(8-mer cyclic peptide) of the above interaction that functions
by binding to TSG101 and preventing its interaction with p6.56
An alternative approach is to develop analogues of the PTAP
motif that will competitively bind to TSG101 in the place
of p6.57 Although in the early stages of development TSG101-
targeting inhibitors represent a very promising approach to
inhibiting HIV in infected individuals. As such inhibitors act
by binding to a host protein, it is hoped that they may not be
as readily susceptible to viral mutations as compounds that
directly bind to viral proteins.
Maturation
Upon release of the immature and non-infectious virus
particles from the cell, the Gag polyprotein is cleaved by
HIV protease to generate the mature Gag proteins MA, CA,
NC, and p6. The proteolytic processing of Gag occurs
in a series of ordered-sequential events, controlled by the
diﬀerential rate of processing at each of the ﬁve cleavage sites.
Gag is initially cleaved in two to give MA-CA-SP1 and
NC-SP2-p6. Subsequent cleavages liberate MA and p6,
followed by proteolysis of the remaining CA-SP1 and
NC-SP2 fragments. Gag-Pol is also cleaved by HIV protease
to release protease, reverse transcriptase and integrase.
Accurate processing of Gag is essential to the infectivity of
the virus particle, making HIV protease a prime target for
inhibition, with multiple compounds having been developed
and available for use in the clinic. As with other compounds
targeting viral proteins however, protease inhibitors are very
susceptible to drug resistance rapidly acquired through
mutation. They are therefore typically administered in
combination with drugs targeting other steps in the HIV
lifecycle (typically reverse transcription). An alternative
approach is to target the homodimerisation of HIV protease,
which is essential for its function. Each subunit contributes an
Asp-Thr-Gly catalytic triad to form the active site, which is
located at the dimer interface (Fig. 8). Several peptides
have been identiﬁed (by logical design or high-throughput
screening) that inhibit dimerisation of HIV protease, as well as
a group of triterpenes identiﬁed by computational screening.58
These compounds are still in the development stage and quite
far from being deployed in the clinic. Despite their novel mode
of action, any HIV protease dimerisation inhibitor will be as
susceptible to acquired drug resistance as those currently on
the market.
Upon cleavage by protease, the processed Gag proteins
co-ordinate the rearrangement of the immature virion to
infectious, mature virus particles. Maturation changes the
morphology of the virus from spherical particles to those
containing a conical capsid core composed of around 1500
CA molecules. The capsid self-assembles through CA/CA
protein–protein interactions and contains the viral RNA
genome in complex with NC, as well as other HIV proteins
required for infection of a new host cell. CA/CA interactions
are central to virus maturation and capsid formation and
potentially an attractive target for the development of novel
antiviral agents that inhibit virus maturation.59 A ﬁrst step in
this process is the discovery of a 12-mer linear peptide (by
phage display) that binds to a conserved hydrophobic groove
in CA, altering the dimer interface and inhibiting assembly of
immature and mature capsid particles in vitro.60 The peptide
was not active in various in vivo viral release assays, probably
due to its inability to cross the cell membrane. The study
nonetheless identiﬁed an allosteric pocket on CA, which could
serve as the starting point for the design and development of a
small molecule maturation inhibitor.
An alternative approach to preventing virus maturation is
to inhibit Gag processing by targeting its interaction with HIB
protease. One of the ﬁrst compounds in this category is
Bevirimat (Fig. 9, also known as PA-457),61 which has been
shown to inhibit the replication of various HIV strains by
blocking the cleavage of the CA-SP1 Gag fragment, preventing
Fig. 8 HIV protease. The functional enzyme is a homodimer, with a
DTG catalytic triad (highlighted) from each subunit making up the
active site at the dimer interface. This ﬁgure was made using PyMol 1.2
and structure 3KF1 from The Protein Data Bank.
Fig. 9 Bevirimat. A maturation inhibitor that prevents the inter-
action of the CA-SP1 fragment with protease, therefore inhibiting its
cleavage.
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the formation of CA and virus maturation. The mechanism of
action of this compound is yet to be fully determined, but there
is strong evidence suggesting that Bevirimat binds to Gag near
or at the CA-SP1 junction, preventing its interaction with
protease (either directly, or by altering the conformation of
Gag). The compound has been undergoing clinical trials,
performing well in early studies, but in vitro studies have
shown that Bevirimat resistance may be acquired by a single
point mutation (A1V) in SP1. This mutant was observed in the
virus from 2 patients (out of 46) participating in Phase IIb
clinical trials, alongside several other mutations in protease
that render reduced susceptibility to treatment.59 As a result,
further development of Bevirimat was halted by the parent
company earlier this year.
Concluding remarks
It has become increasingly clear that we are unlikely to see a
single, ‘magic-bullet’ treatment for HIV, and that the best
approach is likely the combination of compounds that attack
the virus at multiple stages in its lifecycle. The ever-evolving
nature of the virus challenges even this approach, resulting in a
pressing need for new, innovative therapies. Targeting
protein–protein interactions with small molecules holds much
promise, but is a relatively new approach and still in its
infancy. There are multiple challenges associated with
uncovering and developing compounds that inhibit protein–
protein interactions (such as lack of easily identiﬁable
substrate pockets on protein interfaces), causing progress to
be slower than traditional drug discovery approaches (targeting
enzymes and their active sites). The urgent need for new HIV
therapeutics that function via novel and robust mechanisms
however make overcoming these challenges a matter of
priority and urgency.
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